Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

April 30, 2010

Conditions
AnemiaPregnancy Complications
Interventions
DRUG

Ferli-6® (Continental Pharm co., ltd.)

In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.

DRUG

Venofer® (Vifor AG, St. Gallen, Switzerland)

Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.

Trial Locations (1)

10700

Siriraj Hospital, Mahidol University, Bangkok

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vifor Pharma

INDUSTRY

lead

Mahidol University

OTHER

NCT00746551 - Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment | Biotech Hunter | Biotech Hunter